Objective. To estimate the risk of malignancy in a UK cohort of patients with systemic lupus erythematosus (SLE) under long-term review.
There has been interest in the association of autoimmune suggested that malignancy in patients with SLE may occur more commonly than in the general population, rheumatic disease with malignancy for many years. It has been shown that there is an increased risk of either as a consequence of their disease or as a result of treatment. The occurrence of neoplasia has been haematological malignancies, particularly from nonHodgkin's lymphoma, in patients with rheumatoid arthreported to vary between 3.2 and 11.4% [2, [5] [6] [7] [8] [9] [10] . We have reviewed the available literature and analysed the ritis (RA) [1] . A twofold risk of malignancy in patients with systemic sclerosis (SSc) has been shown [2] , as well risk of developing a malignancy in a UK cohort, which has not been documented before. We have looked previas an increased risk of lung cancer in patients with SSc who have underlying pulmonary fibrosis [3] . Sjö gren's ously at the risk of malignancy in a cohort of 150 patients [11] . Our cohort has since expanded by over syndrome has been linked to an increased risk of developing non-Hodgkin's lymphoma [4] . It has been 100 patients and the period of follow-up has increased substantially. In the present study we analyse the occurrence of malignancy in 276 patients with SLE who were our cohort of patients with SLE and a comparable age-and sex-adjusted rate for the general population from were used. The expected number of malignancies (E ) was calculated as the sum of all person-years at risk in the same geographical location. In addition, we sought data to assess whether there was an increased risk of age group i from the study cohort (ni ) multiplied by the age-and sex-specific cancer rates for the southeast malignancy after the use of immunosuppressive drugs in patients with lupus.
of England in age group i (Ri) using the expression The total number of patient-years of follow-up was that they were at risk.
1695, and the median follow-up period was 4.8 yr. Of the total SLE population, females constituted 93.5%, Statistical analysis Observed cancers. All cancers were identified by review males 6.5%, Caucasians 67.4%, Afro-Caribbeans 17.4%, Asians 9.4%, Orientals 3.6% and others 2.2%. of the medical notes. In all cases neoplasia was diagnosed after the onset of clinical features suggestive of malignant In total, 16 malignancies were diagnosed in 15 patients. There were five cases of breast carcinoma, two disease and not through a screening programme (excluding the case of cervical carcinoma, which was found on cases of non-Hodgkin's lymphoma, and one each of carcinoma of the prostate, cholangiocarcinoma, cervical routine screening appropriate to that age group, which is currently available to the general population). The carcinoma, vulval carcinoma, small cell carcinoma of the lung, squamous cell carcinoma of the anal canal, diagnosis of cancer was ascertained by histological examination or autopsy report. A total of 16 malignanccarcinoma of the colon, thymoma and basal cell carcinoma. However, five malignancies (one non-Hodgkin's ies were identified in 15 patients in our cohort. However, five malignancies predated the diagnosis of SLE and lymphoma, two breast carcinomas, one thymoma and one carcinoma of the colon) were diagnosed before the were therefore excluded from the study. A case of basal cell carcinoma was excluded, as no comparable data diagnosis of SLE and were therefore excluded from the final statistical analysis. Basal cell carcinoma was also were available for the general population. The Thames Cancer Registry [13] excluded basal cell carcinoma from excluded from the final analysis, as no comparable figures were available for the general population. All their database. This is because skin lesions are now often treated by general practitioners or in out-patients clinics, patients were Caucasians, comprising one male and 15 females. Death as a direct result of malignancy occurred where data capture facilities are poor or non-existent. The Registry data for the basal cell carcinoma were in six (2.3%) patients, accounting for 22.6% of deaths in our cohort of SLE patients. The mean age of diagnosis substantially incomplete and therefore of limited value.
Expected number of malignancies. Five-year of SLE was 34.7 yr and the mean time between diagnosis of SLE and the occurrence of malignancy was 7.4 yr. annualized age and gender-specific cancer incidence rates per 100 000 population for the southeast of England Table 1 shows the observed number of cancers in lymphoma, the observed number of malignancies was *P < 0.05.
not statistically significantly different from the expected number. There was a 17-fold increase for Hodgkin's lymphoma (SIR 17.82, 95% CI 0.45-99.23, P < 0.05). 1.16, 95% CI 0.56-2.13). Similarly, the estimated risk for cancer (SIR) was not increased in any of the ageWe also analysed whether there was a difference in treatment between those patients with SLE who specific groups. We did find an increased risk from Hodgkin's lymphoma, which was 17-fold above what developed malignancy and those who did not. We found that treatment with azathioprine, hydroxychloroquine would be expected (SIR 17.82, 95% CI 0.45-99.23, P < 0.05). However, this was based on only one case or prednisolone did not constitute an additional risk factor. Only one patient treated with cyclophosphamide and consequently the confidence intervals are wide. Table 3 outlines the major published series to date. developed a malignancy out of a total of 49 patients treated in the cohort; again we did not find a statistically
We selected large cohort studies rather than reviewing individual case reports. In summary, four large studies significant difference between the two groups.
have indicated an overall increased risk when compared with the general population [5, 6, 8, 9] .
Discussion
Ramsey-Goldman et al. [5] found a twofold increased risk from all malignancies (SIR 2.0, 95% CI 1.4-2.9). We analysed the occurrence of malignancy in a large group of patients with SLE in the UK. Malignancy They also found that lung cancer was the only individual cancer that was increased in all women (SIR 3.1, 95% occurred in 5.4% of our 276 patients with SLE. However, to address the question whether SLE is an additional CI 1.3-7.9), and the risk of breast carcinoma was also increased in Caucasian women with lupus (SIR 2.9, 95% risk factor for the development of malignancy, we defined the at-risk period strictly as the time to onset CI 1.4-6.4). Mellemkjoer et al. [6 ] also suggested that there was an increased risk of developing non-Hodgkin's after the diagnosis of SLE. Within this definition of the at-risk period, the incidence of malignancy fell to 3.6%.
lymphoma [relative risk (RR) 5.2], lung carcinoma (RR 1.9) and liver cancer. However, there were multiple The overall age and sex-standardized incidence rate was not different from that of the general population (SIR potential errors that may have exaggerated this risk. CIN, cervical intraepithelial neoplasia; NHL, non-Hodgkin's lymphoma; ( increased.
They used the Hospital Discharge Registry to establish haematological malignancies. Of the 1426 RA patients, their lupus cohort, which may represent the more severe four had lymphoma, two had leukaemia and one cases of SLE. Also, when the medical case notes were developed a myeloma. The prevalences reported in two reviewed for some of the patients, it was found that not studies for patients with rheumatoid arthritis in the all of the patients fulfilled the ARA criteria for SLE.
absence of immunosuppressive treatment were 0.08 and They also found that some patients represented in their 1.56% respectively [20, 21] . cohort actually had a diagnosis of discoid lupus.
Interestingly, both the patients who developed Petterson et al. [8] suggested that there was an lymphoma in our study had both SLE and Sjö gren's increased risk for all malignancies but found a dramaticsyndrome. The relative risk for primary Sjö gren's synally increased risk ( RR 44, 95% CI 11.9-111) based on drome patients developing non-Hodgkin's lymphoma four cases of non-Hodgkin's lymphoma. Lewis et al. [9] has been estimated to be approximately 40-fold higher also suggested an increased risk. He also used hospital than that for age-and sex-matched control subjects in admission records to identify the patients with SLE.
investigations at the National Institute of Health [19] . Again, this may have exaggerated the risk as they may However, this may be a slight overestimate. We have have included patients with more severe SLE. Canoso also found that patients with Sjö gren's syndrome have and Cohen [10] suggested that there was perhaps an an increased risk of developing non-Hodgkin's increased frequency, 11.4% of their cohort of 70 patients lymphoma [4] . The prevalence of malignant nonwith SLE developing a malignancy. However, they had Hodgkin's lymphoma in Sjö gren's syndrome patients an excess of superficial epithelial lesions (three cervical was estimated to be 4.3%, whereas the prevalence in intraepithelial neoplasias and one Bowen's carcinoma two studies for patients with RA in the absence of of the skin).
immunosuppressive treatment was 0.08 and 1.56% Abu-Shakra et al. [2] noted that the overall risk of respectively [22, 23] . cancer was not increased in their cohort of SLE patients,
The reason lymphoma occurs more commonly in but there was a 4.1-fold increased risk for haematological patients with SLE than in the general population is malignancies, and only non-Hodgkin's lymphoma (three unknown. A side-effect of immunosuppression is a cases) was significantly associated with an increased risk possibility, as is intercurrent viral infection due to, for (SIR 5.4). This association is far smaller than that example, Epstein-Barr, herpes simplex, herpes zoster reported by Pettersson et al. [8] (SIR 44) (based on and polyoma viruses, which are potentially oncogenic. four cases). The general impression from these studies
Patients who have had a renal transplant are known to remains that there may be an increased risk, particularly have an increased risk of cancer [22] . They are, however, from haematological malignancies and breast and lung treated with much higher doses of immunosuppressive carcinomas.
agents than patients with lupus. In the studies of Series looking into the cause of death in cohorts of
Pettersson et al. [8] and Abu-Shakra [2] and in our patients with lupus do not give a true incidence of study, the use of cytotoxic agents was not related to the malignancy, as they do not mention whether any occurrence of malignancy. It may be that the disease tumours had been treated successfully (as not all maligitself confers an increased risk. Patients with SLE have nancies cause death) [15] [16] [17] [18] . Therefore these series may defects in both their cellular and humoral immune underestimate the incidence of malignancies.
systems. Prolonged stimulation of B lymphocytes There are numerous anecdotal reports of haematotogether with defective immune surveillance could result logical malignancies in patients with SLE; in the majority in the formation of autonomous B-cell clones. It is of patients SLE precedes the diagnosis of lymphoprolifpossible that malignant lymphoma, RA and SLE are erative disease. Patients with lymphoma may present manifestations of the same underlying disturbance, and with clinical and laboratory features suggestive of automay be ascribed to chronic antigenic stimulation [23] . immunity, including fever, rashes, arthralgias and Two studies have found an increased risk of breast autoantibodies. Our patients certainly fulfilled the carcinoma [4, 7] . Oestrogenic hormones have been revised ARA criteria for the classification of SLE [12] , suggested as a possible causal factor in the development and several years had lapsed between the diagnosis of of SLE. Risk factors such as low parity or nulliparity SLE and malignancy.
and large body size with truncal obesity are well-known It has been shown previously that patients with RA risk factors for the development of breast cancer [24, 25] . are at increased risk of haematological malignancies [1] .
However, large multicentre studies are required to Abu-Shakra [2] compared the risk of cancer in their address adequately the risk of developing malignancies cohort of SLE patients with RA and SSc. It was found in large cohorts of patients with SLE and to address that the overall risk of cancer was not increased in RA issues such as associated risk factors and additional compared with the general population, but a twofold confounding factors, such as deprivation and exposure increased risk was observed in patients with SSc comto therapy. The chance of detection of a malignancy pared with the general population. The overall SIR in may vary due to factors such as access to health services, the SLE cohort was significantly lower compared with which vary widely and are not uniformly available (cf. that in patients with RA (SIR 0.65, 95% CI 0.41-0.96) the USA), and may therefore underestimate the risk of and patients with SSc (SIR 0.4, 95% CI 0.26-0.60). None of the 248 patients in the SSc cohort developed malignancy.
